CN Patent

CN118697729A — 一种含有水飞蓟宾的组合物

Assigned to Tianjin Tasly St Specialty Pharmaceutical Co ltd · Expires 2024-09-27 · 2y expired

What this patent protects

本发明涉及一种含有水飞蓟宾的组合物在治疗肝纤维化中的应用。一种含有水飞蓟宾的组合物，包含水飞蓟宾和卡维地洛作为有效成分。本发明公开的水飞蓟宾组合物能显著下调Col1a1，Col1a2(Col3a1)，Mmp2mRNA的表达水平，能有效改善化学性肝损伤、胆汁淤积型肝病、非酒精性脂肪肝等多种慢性肝病及其引起的肝脏纤维化病变程度。

USPTO Abstract

本发明涉及一种含有水飞蓟宾的组合物在治疗肝纤维化中的应用。一种含有水飞蓟宾的组合物，包含水飞蓟宾和卡维地洛作为有效成分。本发明公开的水飞蓟宾组合物能显著下调Col1a1，Col1a2(Col3a1)，Mmp2mRNA的表达水平，能有效改善化学性肝损伤、胆汁淤积型肝病、非酒精性脂肪肝等多种慢性肝病及其引起的肝脏纤维化病变程度。

Drugs covered by this patent

Patent Metadata

Patent number
CN118697729A
Jurisdiction
CN
Classification
—
Expires
2024-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Tasly St Specialty Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.